Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Catenae Readies "Covid-19 Passport"

Mon, 18th May 2020 10:51

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Monday and not separately reported by Alliance News:

----------

Catenae Innovations PLC - Digital media - Started trialling and finalisation of Cov-ID app, which will record Covid-19 tests, both antigen and antibody tests. This will allow people to share their status - unexposed, active or recovered. In other words, a "Covid-19 passport".

----------

Sylvania Platinum Ltd - Platinum group metals production - Sylvania Dump Operations started at scaled-down levels on May 1. Now all six operations are now running, albeit at reduced but stable throughput, and it has started to dispatch PGM concentrate.

----------

Alliance Pharma PLC - Healthcare - Majority of employees now working from home with minimal operational disruption. Shanghai office fully operational from early April. Reported impact on year-to-date revenue due to Covid-19 but has started to see a return in consumer confidence starting in key market China.

----------

Inland Homes PLC - Brownfield housebuilding - To reopen sales and marketing suites from May 22 onwards, albeit in line with health protocols and social distancing guidelines. Expects to see sustained demand and housing shortages in south and south east of England.

----------

e-Therapeutics PLC - Drug discovery - Initiates experimental testing on first set of compounds for treatment of Covid-19 identified using network-driven drug discovery platform. Company to work with WuXi AppTec to perform studies.

----------

Open Orphan PLC - CRO pharmaceutical services - Confirmed that MasiQ Covid-19 antibody microarray machine is on site at hVIVO laboratory in east London and is undergoing testing. Expected to be fully operational within two weeks following which it will have capability to undertake up to 3,000 tests a day. Will enter discussions with channel partners to secure testing volumes and determine pricing.

----------

eEnergy Group PLC - energy-efficiency-as-a-service - Launches Covid-19 specialist sanitation service for schools in UK and Ireland. Will offer service alongside provision of LED lighting for fixed monthly service fee.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
29 Jun 2010 16:00

UK SMALLCAP ROUNDUP: E-Therapeutics Seeks Pharma Alliances

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps E-THERAPEUTICS PLC (ETX.LN), a U.K. drug developer, said Tuesday its focus this year and next will be on clinical trials of its experimental medicines an

Read more
29 Jun 2010 12:06

INTERVIEW: E-Therapeutics Readies Trials, Seeks Alliances

By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--U.K. drug developer e-Therapeutics PLC (ETX.LN) Tuesday said its focus this year and next will be on clinical trials of its experimental medicines and securing alliances with pharmaceutical companies. E-Therapeutics, which uses

Read more
29 Jun 2010 11:03

Small caps round-up: Northern Bear, Airsprung, Pursuit Dynamics...

Support services group Northern Bear stretched its strong run Tuesday after claiming a good start to the new financial year, with its order book and pipeline well up on a year ago. "The board is pleased to announce that the new financial year has started well, with strong order books and a healthy

Read more
29 Jun 2010 08:01

E-Therapeutics Loss Widens; In Talks With Drug Makers

LONDON (Dow Jones)--Drug discovery company e-Therapeutics PLC (ETX.LN) Tuesday reported a wider fiscal-year loss and said it remains in talks with drug makers about commercial collaborations. E-Therapeutics, which uses computer software to develop new drugs, added the first of several planned Ph

Read more
2 Mar 2010 16:33

Chairman's wife buys Redrow shares

Redrow chairman Steve Morgan's wife has bought 100,000 shares in the housebuilder taking their combined stake to 29.95%. Fiona Morgan paid 131.5p a share for the 100,000 shares. The total cost was £131,500. Morgan founded Redrow in 1974 and floated the company 20 years later. He also owns Wolver

Read more
27 Jul 2009 08:38

e-Therapeutics narrows losses

Drug discovery and development company e-Therapeutics said annual losses narrowed and it remains confident of becoming cash generative. For the year ended 31 January loss before tax narrowed to £1.96m from a loss of £2.2m the year before. Revenue increased to £67,000 from £64,000 the previous year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.